Fadogia Agrestis
Fadogia agrestis (Nigerian aphrodisiac shrub)
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA evaluated; no human safety or efficacy data
Reference only. Not medical advice.
What can go wrong
No established human safety profile. Rodent studies report testicular toxicity, altered testicular histology, and potential liver/kidney effects at higher doses. Purity and dosing of commercial products are unverified and frequently inconsistent. Given the absence of human trials and the presence of animal testicular-toxicity signals, the prudent clinical position is that fadogia agrestis should not be used outside of formal research.
This is something to take to a clinician. The Atlas can tell you what is known about fadogia agrestis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A Nigerian shrub promoted as a luteinizing-hormone-like testosterone booster. There are NO human randomized controlled trials of fadogia agrestis. The available evidence is limited to rodent studies, some of which report increased testosterone at low doses but also document testicular toxicity and organ damage at higher doses. The gap between its influencer-driven popularity and its evidence base is one of the largest in the entire natural-testosterone category, which is why this entry is a consumer-protection caution.
Heavy influencer hype, zero human trials, and animal data showing testicular toxicity.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.
How it is supposed to work
Marketing claims it acts like luteinizing hormone to stimulate Leydig-cell testosterone production. This is extrapolated from rodent studies; the human mechanism, effective dose, and safe dose are all unknown.
Why this is a caution entry
The same rodent literature cited to claim a testosterone benefit also reports dose-dependent testicular damage, reduced sperm parameters, and signs of organ toxicity. Without human pharmacokinetic or safety data, there is no established safe dose, no known long-term effect on fertility, and no monitoring standard. Consumers are effectively self-experimenting with a compound whose animal data raise direct red flags for the organ men are trying to support.
Safety in detail
- No human randomized controlled trials of any kind
- Rodent testicular toxicity at higher doses and longer exposures
- No established safe dose or duration in humans
- Unknown effect on human fertility
- Commercial products are largely unstandardized and unverified
- No monitoring protocol exists because no human pharmacology is characterized
What people get wrong
Often saidFadogia is a natural testosterone booster proven in studies
ActuallyMisleading. The only studies are in rodents. No human RCT has ever tested it for efficacy or safety.
Often saidIf it raises testosterone it must be safe
ActuallyThe same animal studies that show a testosterone rise at low doses show testicular toxicity at higher doses. There is no human safe-dose data at all.
Often saidPopular among podcasters means vetted
ActuallyPopularity was driven by media discussion, not by clinical validation. Influence and evidence are not the same thing.
Who profits, and who pushes back
Toxicology and andrology commentators
Recommending a compound for testicular health when the only existing data show testicular toxicity in animals inverts the precautionary principle.
Andrew Huberman
Widely credited as the primary driver of consumer interest in fadogia agrestis after discussing it (often paired with tongkat ali) as part of his own supplement routine. Important to be factual and precise: there is no public evidence that Huberman has a paid promotional relationship specifically for a fadogia agrestis product, and he has stated he tries to disclose conflicts. He has had documented commercial relationships with general supplement companies in the broader wellness space (for example, AG1/Athletic Greens served as a long-running named podcast sponsor, and he has had partnerships such as Momentous/Thorne and others); those sponsorships are distinct from fadogia itself. The fadogia interest appears driven by his editorial discussion rather than a fadogia-specific paid deal. Sponsorship arrangements change over time and should be verified against current disclosures.
Biohacker and TRT-adjacent influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Many sell or affiliate-market fadogia/tongkat 'stacks' following the podcast-driven demand
How we got here
Fadogia agrestis was used traditionally in parts of West Africa as an aphrodisiac. It was essentially unknown in the Western supplement market until the early 2020s, when it gained rapid popularity after being discussed in the podcast and biohacking ecosystem. Demand outpaced any clinical research, and products proliferated with little standardization.
- TraditionalWest African aphrodisiac use
- 2005-2008Yakubu rodent studies, including toxicity findings
- ~2021-2022Surges in popularity via podcast/biohacker discussion
- 2023-2025Widely sold despite continued absence of human trials
Set against the alternatives
Unlike the other ingredients it is grouped with, fadogia agrestis sits at the very bottom of the evidence ladder: where ashwagandha, Tongkat Ali, and fenugreek each have at least small human randomized trials suggesting a modest effect, fadogia has no human RCTs at all and its reputation rests almost entirely on rodent studies and influencer promotion. Tribulus is a useful contrast in the opposite direction - it has been studied in humans repeatedly and largely failed, so its low rating reflects negative evidence, whereas fadogia's reflects an absence of evidence combined with an active toxicity signal. In practical terms, fadogia is distinguished from its peers not by a larger effect but by a worse evidence-to-risk profile.
| Agent | Human RCTs | Safety signal | Evidence verdict |
|---|---|---|---|
| Fadogia agrestis | None | Rodent testicular toxicity | Unproven, caution |
| Ashwagandha | Several small RCTs | Generally well tolerated | Modest, stress-mediated |
| Tongkat Ali | Some human trials | Mostly mild reports | Small, mainly hypogonadal |
| Fenugreek | Several small RCTs | Generally mild | Mixed, small effect |
| Tribulus terrestris | Multiple negative trials | Rare hepatic case reports | No reliable T effect |
What we do not know
- Is there any dose safe for human testicular tissue over time?
- Does any human testosterone benefit exist at all?
- What are the long-term fertility consequences?
What could change
Basic human safety dataAny controlled human pharmacokinetic or toxicity study would be foundational and currently absentActive-compound identificationCharacterizing which constituents (if any) drive the rodent androgenic signalHepatic and testicular monitoringCase surveillance for liver and gonadal effects in current usersAdulteration testingIndependent assays for undisclosed ingredients in marketed products
At a glance
- Origin
- West Africa (Nigeria)
- Human RCTs
- None
- Key safety signal
- Testicular toxicity in rodents at high doses
- Primary popularity driver
- Influencer podcasts
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Fadogia Agrestis. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Yakubu et al. (rodent series)2005-2008
Aqueous Fadogia agrestis stem extract raised serum testosterone in rats at lower doses but produced testicular toxicity, distorted testicular histology, and adverse organ effects at higher doses and longer durations
Human RCTsN/A
None exist. All efficacy and safety claims are extrapolations from animal data.